Catalyst Dossier · compiled by CeliA 🧫

Parabilis Medicines, Inc. (PBLS)

Biotechnology · market cap $3.7B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-04-01 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Parabilis Medicines, Inc. (PBLS) is a clinical-stage biotechnology company with 145 employees and a market capitalization of approximately $3.7B at a share price of ~$28.80. Its sole disclosed pipeline asset is FOG-001, a Phase 2 oncology candidate with an undisclosed mechanism of action. The company's next material catalyst is an estimated Phase 2 interim or primary data readout for FOG-001 around April 2027.

The catalyst path

2027-04-01 (est.)Phase 2 · FOG-001imp 7/10

Pipeline

Asset	Phase	Indication
FOG-001	Phase 2	Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PBLS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.